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The Ras/MAPK pathway is critical for human development and plays a central role in the formation and pro-
gression of most cancers. Children born with germ-line mutations in BRAF, MEK1 or MEK2 develop cardio-
facio-cutaneous (CFC) syndrome, an autosomal dominant syndrome characterized by a distinctive facial
appearance, heart defects, skin and hair abnormalities and mental retardation. CFC syndrome mutations in
BRAF promote both kinase-activating and kinase-impaired variants. CFC syndrome has a progressive pheno-
type, and the availability of clinically active inhibitors of the MAPK pathway prompts the important question
as to whether such inhibitors might be therapeutically effective in the treatment of CFC syndrome. To study
the developmental effects of CFC mutant alleles in vivo, we have expressed a panel of 28 BRAF and MEK
alleles in zebrafish embryos to assess the function of human disease alleles and available chemical inhibitors
of this pathway. We find that both kinase-activating and kinase-impaired CFC mutant alleles promote the
equivalent developmental outcome when expressed during early development and that treatment of CFC-
zebrafish embryos with inhibitors of the FGF-MAPK pathway can restore normal early development.
Importantly, we find a developmental window in which treatment with a MEK inhibitor can restore the
normal early development of the embryo, without the additional, unwanted developmental effects of the drug.
INTRODUCTION
Perception of the RAS-RAF-MEK-ERK mitogen-activated
protein kinase (Ras/MAPK) signalling components, known
for their role in signalling and cancer, has been altered by
the discovery that germ-line mutations underlie a series of syn-
dromes with overlapping features. These Ras/MAPK syn-
dromes include the genetic disorders neurofibromatosis Type
I, LEOPARD syndrome, Noonan syndrome, Costello syn-
drome, capillary malformation arteriovenous malformation
syndrome and cardio-facio-cutaneous (CFC) syndrome. The
overlapping clinical features, including heart defects, distinc-
tive facial appearances, skin and hair abnormalities, short
stature and mental retardation, propelled the discovery that
these syndromes are caused by germ-line mutations in the
same genetic pathway, and reflect a common underlying mol-
ecular pathogenesis through mutation of core components of
the Ras/MAPK signalling pathway. Characteristics that dis-
tinguish between the syndromes coupled with the now avail-
able sequence-based genetic testing, has been an important
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step forward in diagnosis and characterization of this group of
disorders (1).
With refined diagnostic tools in hand, there is a need to
understand the nature of the CFC mutations in vivo and
develop therapeutic approaches. Activated in most cancers,
the Ras/MAPK signalling pathway is among the key drug
targets for anti-cancer therapies (2). The pathway is activated
in tumour cells through many different ways, including
mutation of the components themselves, often through
gain-of-function mutations. For example, the BRAF oncogene
is mutated in over 60% of melanomas (3). The ‘addiction’ of a
broad spectrum of tumours to the continued activation of
Ras/MAPK signalling has made it a prime target for pharma-
cological intervention, and specific BRAF and MEK inhibitors
are currently in clinical trails (2,4–6). Although patients with
Costello syndrome are prone to developing neural crest malig-
nancies, it is not clear if CFC patients have an elevated risk of
developing cancer, with only a few individuals developing
neoplasms in different tissues (1). CFC BRAF mutations
have a wider mutation spectrum than BRAF-nevi/cancer
mutations, yet two notable similarities emerge. First, the spec-
trum of CFC and nevi/cancer mutations overlap, some with
identical mutations. Second, CFC and nevi/cancer disease
BRAF alleles result in both kinase-activating and
kinase-impaired activities in vitro (7–10). Although in vitro
functional assays have established the effects of the CFC
mutation on kinase activity, an outstanding question is how
both activating and inactivating BRAF mutations give rise to
the same clinical phenotype. We wanted to establish if CFC
allele mutations promote the same phenotypic outcome in
vivo, and which mutations are sensitive to currently available
MAPK-pathway inhibitors (11,12).
Animal models play an important role in furthering our
understanding of the pathogenesis associated with
Ras/MAPK syndromes disease alleles. Studies in transgenic
Drosophila have shown that both loss-of-function and
gain-of-function LEOPARD and Noonan syndrome PTPN11
mutations can give rise to similar developmental phenotypes
in the eye and wing veins of the fly, suggesting a rationale
for how different PTPN11 mutations can give rise to syn-
dromes with clinically overlapping phenotypes (13,14). In
zebrafish, loss of PTPN11 (SHP-2) and expression of
Noonan and LEOPARD syndrome alleles cause early cell
movement phenotypes and developmental features that
overlap with the principal features of the syndromes, including
growth and heart defects, craniofacial abnormalities and
ocular hypertelorism (15). Adult zebrafish and mouse
models of H-RasG12V reveal overlapping phenotypes with
Costello syndrome patients (16,17). Both models provide
insight into the syndrome. The zebrafish H-RasG12V model
suggests that oncogene-induced senescence contributes to the
pathogenesis of Costello syndrome (16), and the
H-RasG12V-induced cardiomyopathies in the mouse can be
prevented with treatment with standard anti-hypertensive
therapies (17). Thus, animal models can rapidly reveal the
nature of the human genetic mutation in vivo, their impact
upon development, and provide insight into evaluating new
therapeutic opportunities.
Cell culture studies have shown that CFC MEK mutant
alleles are sensitive to the widely used MEK inhibitor,
U0126 (12). Most CFC patients have mutations in BRAF,
and it has been predicted that BRAF CFC alleles might also
be sensitive to MEK inhibition (12). Given that MAPK signal-
ling plays an important role in cell movement in zebrafish gas-
trulation (18), we wanted to establish the effects of BRAF and
MEK CFC mutant alleles in early development. Here, we use
the zebrafish system to explore the function of a panel of 28
BRAF and MEK mutant alleles in development, and to
assess the potential of using small molecule inhibitors to
prevent these defects. We show that the expression of both
BRAF and MEK kinase-activating and kinase-impaired CFC
and melanoma alleles cause similar phenotypes with signifi-
cant cell movement defects in early embryogenesis. In
addition, we find that the cell movement phenotypes of both
the kinase-activating and kinase-impaired CFC alleles can be
prevented by treatment with specific MEK inhibitors. Treat-
ment is most effective within a developmental time window:
a 1 h treatment at the start of significant convergence–
extension cell movements is necessary and sufficient to
prevent the CFC induced developmental effects. FGF-MAPK
signalling is active during early embryogenesis, and therefore
we hypothesized that the inhibition of endogenous FGFR sig-
nalling might partially prevent the developmental effects of
CFC alleles in gastrulation. We show inhibition of upstream
signalling is also able to restore normal development for
CFC, except for the most active BRAF melanoma allele,
demonstrating the importance of overall activation of the
MAPK signalling during development. With sequencing-
based genetic tests available to identify individuals with
mutations, our work provides a rationale for varied kinase
activity in the CFC allele spectrum and will contribute to
the clinical discussion about the treatment strategy for individ-
uals with CFC syndrome using currently available MAPK-
pathway inhibitors.
RESULTS
CFC allele activity in zebrafish development
The Ras/MAPK pathway is highly conserved in vertebrates,
and we have used the zebrafish system to examine the func-
tional activity of CFC alleles and their response to chemical
inhibition (Fig. 1), based on the important role of the
FGF-MAPK pathway during early embryonic development.
Within the past two decades, the zebrafish system has
become established as a useful model for vertebrate develop-
mental biology and disease (19). Organogenesis in the trans-
parent embryos can be followed in vivo under the light
microscope, and specific genetic and chemical models of
human developmental syndromes have advanced our under-
standing of human disease and treatment (19–21).
Vertebrates share a conserved body plan that is established
through gastrulation, the critical process that involves extensive
cell movement and shapes the relatively unstructured early
embryo into a gastrula with conserved germ layers (18).
FGF-MAPK signalling contributes to the establishment of the
dorsoventral axis, in which the highest concentration of
FGF-signalling specifies the dorsal most part of the embryo
and acts as a local attractive centre for convergence–extension
movements within the gastrula (18). Expression of activated
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FGF-RAS-RAF-MEK signalling in zebrafish embryo causes a
loss of localized FGF-concentration that would normally
promote convergence of cells towards the dorsal midline, but
does not affect the continued epiboly movements and thereby
results in an elongated embryo (22–24). Loss of the down-
stream ERK1 or ERK2 kinases in zebrafish also results in dis-
tinct convergence–extension cell migration defects during
gastrulation (25), as does the expression of Noonan and
LEOPARD syndrome SHP-2 alleles (15).
Building on these observations and coupled with the tract-
ability of the zebrafish system, we reasoned that the expression
of CFC mRNA in zebrafish embryos would allow us to rapidly
assess the functional significance of BRAF, MEK1 and MEK2
kinase-active and kinase-impaired variants within a develop-
mental context, and test the action of currently available
FGF-MAPK-pathway inhibitors on the CFC allele phenotypic
outcome (Fig. 1 and Table 1). We began by injecting mRNA
into the one-cell zebrafish embryo and closely monitoring
development of the effects of the high-kinase, most common
variant in melanoma, BRAFV600E, the kinase-impaired CFC/
melanoma variant, BRAFG596V and the most common
kinase-activating variant in CFC syndrome, BRAFQ257R.
Early cell-cleavage was not affected, and initial gastrulation
appeared normal. However, by 12 h post-fertilization (hpf),
the embryos were highly elongated (Fig. 1A). Later stages of
development showed that anterior embryonic structures still
formed, but that there was a lack of tail formation, similar to
ectopic MAPK signalling (22–24). In addition, the embryos
expressing the high-kinase BRAFV600E had a complete loss of
eye development (Fig. 1A). Importantly, injection of normal
human BRAF (wild-type, WT) into the embryo caused no evi-
dence of elongation, suggesting that the expression of BRAFWT
does not alter normal development, even when ectopically
expressed (Fig. 1A). Western blotting confirmed expression of
the myc-tagged BRAFWT and BRAF disease alleles (Fig. 1B).
Analysis of kinase-active and kinase-impaired CFC and
melanoma alleles
The Ras/MAPK signalling pathway is highly conserved in
humans and zebrafish. As in nevi/melanoma, the BRAF-CFC
mutations result in both kinase-activating and kinase-impaired
activities (2,7–9,26). Notably, all MEK1 and MEK2 CFC
mutations are kinase active (7,27) (K.A.R., unpublished
data). To assess the effects of the kinase-active and
kinase-impaired melanoma and CFC alleles in vivo, we gener-
ated a panel of 20 BRAF and MEK disease variants in addition
to the normal and engineered BRAF and MEK alleles
(7,27,28) (Figs 1, 2 and Table 1), and expressed each individu-
ally by mRNA injection in the zebrafish embryo. First, we
tested a panel of BRAF CFC and melanoma alleles, and
found all BRAF variants promote an elongated embryonic
phenotype, suggesting that in vivo, kinase-active and
kinase-impaired BRAF alleles can promote the same develop-
mental outcome (Fig. 2A, B and Table 1). To further test our
system, we expressed normal and CFC syndrome activating
MEK1 and MEK2 alleles, and also found that the disease
alleles, but not the normal MEKs (MEK1WT, MEK2WT), pro-
moted an elongated embryonic phenotype (Fig. 2C and
Table 1). Western blotting of zebrafish embryonic lysates for
total ERK protein and phospho-ERK confirmed that all
BRAF and MEK alleles caused ERK activation in the zebra-
fish embryo (Fig. 2B, D, E). Because the BRAFWT,
MEK1WT and MEK2WT expressing embryos developed nor-
mally, but both kinase-active and kinase-impaired alleles
caused altered embryonic development, this suggested to us
that the in vitro biochemical kinase activity might not
predict the potential for disease development. We found
both constitutively kinase-active and kinase-inactive BRAF
and MEK alleles to also promote an elongated embryonic
phenotype (Fig. 2 and Table 1), suggesting that additional
Figure 1. CFC syndrome alleles promote developmental changes during early embryogeneis. (A) RNA expression of CFC and melanoma variants BRAFQ257R
(kinase-activating, CFC), BRAFG596V (kinase-impaired, CFC and melanoma) and BRAFV600E (very high-kinase, melanoma) cause elongation of the developing
zebrafish embryo at 12 hpf, and severe developmental abnormalities at 24 and 48 hpf. In contrast, embryos expressing BRAFWT undergo normal development at
all stages. No differences were detected in WT or disease allele expressing 4 hpf embryos. (B) Western blotting of zebrafish extracts reveals expression of the
myc-tagged BRAF variants with the 9E10 antibody, and a-tubulin is a loading control.
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interactions in vivo, possibly with endogenous WT BRAF and
MEK, may be capable of altering normal development.
We observed control and CFC BRAFQ257R expressing
embryos in detail and noted initial changes to embryo shape
at 7.5–8.5 hpf (Fig. 3A). As FGF-MAPK signalling is critical
for cell movements during gastrulation, and Noonan and
LEOPARD mutant Shp2 alleles promote defective conver-
gence and extension cell movements (15), we examined
whether early gastrulation movements were affected by the
expression of BRAF and MEK disease alleles using in situ
hybridization markers (15,25). HggI (hatching gland, marker
of anterior–posterior axis) expression remained unaffected,
whereas dlx3 (edge neural plate marker, convergence
marker) was widely modified in the embryos injected with
the disease, but not normal, alleles. This indicates that the
CFC and melanoma alleles disrupt cell movements during gas-
trulation (Fig. 3B and C), similar to expression of activated
FGF-MAPK signalling in zebrafish development (22–24).
The convergence phenotypes appear more severe than the
Shp2 Noonan and LEOPARD syndromes alleles (15),
suggesting Shp2 mutations may act differently than BRAF
and MEK CFC syndrome alleles during gastrulation. The
ability to detect a clear phenotypic readout that could dis-
tinguish between BRAFWT and BRAF disease alleles,
allowed us to use the zebrafish as the basis for further investi-
gation of the CFC-pathway allele function.
BRAF kinase-active and kinase-impaired alleles can
promote an additive effect during development
Our findings, that CFC kinase-impaired mutant alleles behave
similar to kinase-active mutant alleles in vivo, are reminiscent
of the action of both gain-of-function Noonan and
loss-of-function LEOPARD Shp2 disease alleles to promote
ectopic wing vein growth in Drosophila (13,14), and cell
movement phenotypes in zebrafish (15). In zebrafish, Shp2
Noonan and LEOPARD mutant alleles are not additive, and
do not lead to an increase in the number of embryos with a
phenotype in early development (15). This suggests that
Noonan and LEOPARD Shp2 mutations induce the same phe-
notype by activating or inhibiting pathway signalling. We
investigated how BRAF kinase-activating and kinase-impaired
alleles promote similar phenotypes during embryogenesis. We
co-injected suboptimal levels of the kinase-active BRAFQ257R
allele, the kinase-active BRAFS467A or the kinase-impaired
BRAFG596V allele alone or with the BRAFWT allele (Fig. 4).
Co-injection of BRAF CFC mutant alleles with BRAFWT
did not significantly affect the number of embryos with a phe-
notype compared with the injection of the suboptimal BRAF
CFC allele alone. Only 60–66% of the embryos have an
early embryonic phenotype when expressing only one BRAF
CFC allele, or in combination with BRAFWT. In contrast,
co-injection of kinase-active BRAFQ257R with kinase-active
Table 1. Summary of the BRAF and MEK variants expressed in zebrafish
Gene Amino acid change Predicted activity Disease Developmental phenotype in zebrafish (n) Respond to treatment
BRAF Wild-type Wild-type NA No (0/40) NA
A246P ND CFC Yes (31/57) Yes
Q257R Kinase-activating CFC Yes (83/95) Yes
G464V Kinase-activating CFC Yes (25/45) Yes
S467A Kinase-activating CFC Yes (49/57) Yes
K483M Kinase-inactivating Engineered Yes (34/44) Yes
K499E Kinase-activating CFC Yes (23/44) Yes
G534R Kinase-activating CFC Yes (33/38) Yes
N581D ND CFC Yes (23/51) Yes
D594V Kinase-impaired Melanoma yes (43/56) yes
G596V Kinase-impaired CFC and Melanoma Yes (86/104) Yes
T599E/S602D Constitutively active Engineered Yes (36/73) Yes
V600E Kinase-activating Melanoma Yes (68/84) Yes CI-1040
no SU-5402
D638E ND CFC Yes (66/89) Yes
MEK1 Wild-type Wild-type NA No (0/40) NA
F53L Constitutively active Engineered Yes (16/33) Yes
F53S Kinase-activating CFC Yes (20/33) Yes
T55P Kinase-activating CFC Yes (26/45) Yes
K97M Kinase-inactivating Engineered Yes (45/62) Yes
G128V Kinase-activating CFC Yes (22/35) Yes
Y130C Kinase-activating CFC Yes (30/45) Yes
S218D/S222D Constitutively active Engineered Yes (45/55) Yes
DN3DD Constitutively active Engineered Yes (41/60) Yes
MEK2 Wild-type Wild-type NA No (0/40) N/A
F57C Kinase-activating CFC Yes (31/42) Yes
A62P Kinase-activating CFC Yes (25/39) Yes
K101M Kinase-inactivating Engineered Yes (39/52) Yes
G132V Kinase-activating CFC Yes (45/72) Yes
Y134C Kinase-activating CFC Yes (30/54) Yes
S222D/S226D Constitutively active Engineered Yes (33/49) Yes
K273R Kinase-activating CFC Yes (42/63) Yes
NA, not applicable; ND, not determined; n, number.
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BRAFS467A resulted in a significant enhancement of the
number of embryos with an elongated phenotype. In addition,
co-injection of kinase-active BRAFQ257R with kinase-impaired
BRAFG596V also resulted in a significant increase in the
number of elongated embryos. The number of embryos with
a phenotype induced by BRAFQ257R/S467A (91.9%) or
BRAFQ257R/G596V (88.2%) is consistent with the 82–87% of
embryos that develop a developmental phenotype when the
optimal dose is used (Table 1). Our results are consistent
with both the kinase-active and the kinase-impaired BRAF
CFC mutations acting as gain-of-function mutations during
development.
MEK inhibitors can prevent the effects of CFC alleles
We wanted to assess whether currently available MAPK-
pathway inhibitors might prevent the effects of CFC disease
alleles in development. Previous studies have shown that
Figure 2. Analysis and treatment of kinase-activating and kinase-impaired BRAF and MEK disease variants. (A) RNA expression of BRAF CFC and melanoma
variants, as well as engineered BRAF mutations, promotes an elongated embryo phenotype. RNA expression of wild-type BRAF has no effect on development.
The developmental phenotypes caused by the BRAF variants are prevented by treatment with the MEK inhibitor, CI-1040 and the embryo has a normal rounded
shape. (B) Western blotting of zebrafish lysates with anti-ERK and anti-phospho-ERK antibodies reveals a reduction in the ratio of phospho-ERK to total ERK
protein in treated embryos, and a-tubulin is a loading control. (C) RNA expression of CFC MEK variants, the MEK1 constitutively activating (DN3DD) and the
MEK2 kinase-inactivating K101M mutations promotes elongation in the developing embryo. Expression of wild-type MEK1 and MEK2 do not affect devel-
opment. The developmental phenotypes caused by the MEK alleles are prevented by treatment with the MEK inhibitors, CI-1040 and PD0325901. (D and
E) Western blotting of zebrafish lysates with anti-ERK and anti-phospho-ERK antibodies reveals downstream activity of phospho-ERK and confirms the
potency of the MEK inhibitors, and a-tubulin is a loading control.
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cancers with activated BRAF are highly sensitive to MEK
inhibitors (29) and that CFC MEK alleles in cell culture are
sensitive to the widely used MEK inhibitor, U0126 (12).
However, it was unknown whether the CFC kinase-activating
and kinase-impaired BRAF and MEK variants would be sen-
sitive to the inhibition of MEK during development. We
expressed BRAF CFC and melanoma alleles in developing
embryos as before, and at 4 hpf added CI-1040, a clinically
active MEK inhibitor that is the basis for new second-
generation MEK inhibitors (5,6) to the embryo medium. We
found that chemical inhibition of MEK was able to restore
normal development until 10.5 hpf in all embryos expressing
BRAF CFC and melanoma disease alleles (Fig. 2A). We
found a similar result when we expressed CFC and engineered
MEK1 and MEK2 alleles in zebrafish embryos, and treated
with CI-1040 or PD0325901, a derivative of CI-1040
(Fig. 2C). With both BRAF and MEK variants, western blot-
ting confirmed that the ratio of phosphorylated ERK to total
ERK protein was reduced after chemical inhibition of MEK
(Fig. 2B, D, E).
MEK signalling is critical for development, and we have
previously shown that prolonged treatment (up to day 4 pf)
with the pharmacological inhibition of MEK using CI-1040
causes severe axis, heart and craniofacial developmental
abnormalities (30), and we find a similar effect using
PD0325901 (C.A., E.E.P., unpublished data). Although we
were able to restore normal gastrulation in CFC embryos
with CI-1040 and PD0325901 (Fig. 2A and C), treated
embryos subsequently developed axis abnormalities associ-
ated with the effects of the inhibitor later in development
(30). To circumvent this problem, we exposed the most
common BRAFQ257R CFC allele expressing embryos to the
MEK inhibitor for 12 different treatments that varied for the
time of exposure. We found that although all experimental
treatments that involved adding the inhibitor early in develop-
ment prevented embryo elongation (10.5 hpf) (Fig. 5A treat-
ments A–F), a 1 h treatment within a 4.5–5.5 hpf
developmental window was sufficient to restore normal devel-
opment at 24 hpf (Fig. 5A treatment A), without the
additional, subsequent unwanted abnormalities caused by the
inhibitor (Fig. 5A treatments C–F). Treatment within this
early developmental window was necessary, as a 1 h treatment
later in development (Fig. 5B treatment F) was unable to
prevent CFC mutant allele phenotypes, as were the treatments
Figure 3. BRAF and MEK disease alleles promote cell movement phenotypes. (A) The most common CFC varient, BRAFQ257R, was expressed in developing
embryos, and the embryos imaged every hour. Development of the embryos begins to become affected by BRAFQ257R expression between 7.5 and 8.5 hpf. (B)
BRAF and (C) MEK disease variants promote significant changes in cell movement, as revealed by in situ hybridization. The gene expression domain of dlx3 is
altered for both expression pattern and intensity of signal, such that there is no dlx3 detected in the BRAFV600E expressing embryos. HggI expression remains
unaffected. The bottom panel shows the lateral view of the same embryos.
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that had CI-1040 throughout the experiment, with the excep-
tion of the 4.5–5.5 hpf developmental window (Fig. 5B
treatment B).
Distinguishing between BRAF alleles for sensitivity to
pathway inhibition
The ability to treat kinase-active and kinase-impaired CFC
embryos suggests correction of signalling downstream of the
CFC mutation is sufficient to restore normal development.
This is consistent with the sensitivity of cancers expressing
RAS and RAF high-kinase oncogenes to MEK inhibitors
(5,6,29), and the sensitivity of CFC MEK alleles to MEK inhi-
bition in cell culture (12). FGF-MAPK signalling plays an
important role during embryonic cell movements in zebrafish.
Unlike in a cancer cell with a BRAF mutation, a developing
animal with a BRAF or MEK CFC mutation also has endogen-
ous FGFR signalling. We hypothesized that total MAPK sig-
nalling may underlie CFC syndrome development and that
suppression of endogenous FGFR signalling could partially
suppress the activity of the effects of the downstream CFC
alleles. As with the MEK inhibitor, we treated 4 hpf
embryos expressing BRAF (Fig. 6A) and MEK (Fig. 6B)
CFC and melanoma mutant alleles with SU-5402, an inhibitor
of the FGF receptor 1 (FGFR1). Western blotting confirmed
reduction of phosphorylated ERK after SU-5402 treatment
(Fig. 6C). We found the development to be normal for all
treated embryos expressing BRAF and MEK disease alleles
at 10.5 hpf, with the exception of the very high-kinase activity
melanoma mutant BRAFV600E (Fig. 6A and B). The most
common mutation in melanoma and nevi, BRAFV600E is one
of the highest kinase activity mutants, has transforming
activity and is sufficient to promote nevi and melanoma devel-
opment, as well as other cancers, in animal models (3,26,31–
34). This suggests that total levels of MAPK signalling may be
responsible for the action of the CFC alleles, and reduction of
either endogenous FGF signalling or downstream MEK signal-
ling can prevent some of the pathological function of the
alleles.
DISCUSSION
Our study addresses the in vivo action of CFC mutant alleles
and may point to a potential therapeutic approach for individ-
uals with CFC syndrome. First, we have demonstrated that
CFC mutant alleles cause similar developmental phenotypes
in an in vivo zebrafish model system, despite their in vitro
kinase activity. Second, we have used our model system to
explore the therapeutic potential of small molecule inhibitors
to prevent the in vivo activity of CFC mutations during early
development. We have evaluated both the developmental
activity and the therapeutic potential of 18 human CFC and
three melanoma disease alleles, as well as three different
small molecule inhibitors, in 12 treatment conditions. In this
work, zebrafish embryos are injected at the single cell stage
with RNA of the human disease allele, or with control RNA,
and the phenotype of the embryo assessed by 10 h (Figs 1, 3
and 7A). Embryos normally express FGF-MAPK signalling
during development in a localized manner to shape the devel-
opment of the embryos during gastrulation (18). We found
BRAF and MEK kinase-active and kinase-impaired disease
variants interfere with convergence–extension cell move-
ments during gastrulation (Fig. 1), providing insight into
how similar clinical CFC phenotypes are caused by
kinase-activating and kinase-impaired alleles. Future studies
will reveal how the effects on early cell movement (Fig. 1)
correlate with disease allele penetrance and disease presen-
tation in humans.
In our in vivo animal system, and in the context of endogen-
ous signalling, we find CFC alleles with kinase-inactivating
mutations, as defined in vitro, promote the same phenotype
as kinase-active alleles. One possibility is that BRAF
kinase-impaired proteins interact with CRAF to stimulate
MEK-ERK signalling (9,10,35). Kinases frequently act
through dimerization, including BRAF and CRAF (10,36),
and crystal structures of MEK predict MEK1 and MEK2
self associate via a homodimerization interface to form
stable dimers (37). Such mechanisms may be at work in our
zebrafish studies, providing the molecular context for
kinase-impaired BRAF and MEK alleles to be able to
promote active signalling of the pathway, including the engin-
eered kinase-inactive alleles (36) as determined by in vitro
kinase assays (Fig. 3). Another possibility is that dysregulation
of Ras/MAPK signalling through gain-of-function or
loss-of-function mutations may cause similar disease pheno-
types (38). As an important example, the disease spectrum
associated with varying SHP-2 mutations in Noonan syndrome
and cancer argue against SHP-2 activity as the defining predic-
tor of disease outcome (39). Both loss-of-function and
gain-of-function mutations in SHP-2 lead to the clinically
Figure 4. BRAF kinase-active and kinase-impaired alleles can promote an
additive effect during development. Embryos co-expressing combinations of
suboptimal doses (15 pg) of kinase-active (BRAFQ257R, BRAFS467A) and
kinase-impaired (BRAFG596V) CFC alleles or BRAFWT mRNA were assessed
for the elongation phenotype at 10 hpf. The number of elongated embryos did
not change significantly upon expression of a single BRAF CFC allele (15 pg),
or in combination with BRAFWT (for a total of 30 pg). A significant increase
in the mutant phenotype was induced by co-injections of BRAFQ257R with
BRAFS467A (P , 0.0001) or BRAFQ257R with BRAFG596V (P ¼ 0.0003) com-
pared with the BRAF CFC allele co-injected with BRAFWT as indicated by x2
tests. The numbers in the bars indicates the percentages of elongated embryos;
n is the number of injected embryos.
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similar LEOPARD and Noonan syndromes, and expression of
LEOPARD and Noonan syndrome alleles in zebrafish and
Drosophila produce equivalent developmental phenotypes
(15–17). Our work suggests that both kinase-active and
kinase-impaired CFC alleles are effectively gain-of-function
mutations and activate the pathway because combinations of
active and impaired BRAF mutant alleles can promote an
additive effect during early development (Fig. 4).
Designing new therapies for rare birth disorders is proble-
matic due to the great costs and research efforts of drug
development, and the required clinical safety and efficacy
testing for new therapeutics (40). Since the Ras/MAPK
pathway has been a prime target for cancer therapeutics,
application of these small molecule inhibitors presents a
possible therapeutic avenue, since the underlying molecular
dysfunction is common. Previously, the activity of CFC
MEK alleles has been shown to be sensitive to MEK inhibi-
tors in cells (12). Direct testing of the effects of anti-cancer
therapeutics on BRAF and MEK CFC characteristics in zeb-
rafish is an important next step in exploring the therapeutic
potential for CFC syndrome. Using our model, we have
tested the ability of FGF-MAPK inhibitors to prevent the
developmental effects of CFC and melanoma disease
alleles (Fig. 7B). We found that MEK inhibitors prevent
the cell migration defects caused by the disease alleles,
and also that additional developmental side-effects of the
drug could be avoided by treating the embryos within a
specific developmental time-window (Fig. 5A). These
results suggest that future studies in pre-clinical models of
CFC should explore if similar drug treatment time
windows may help ease the developmental abnormalities
and symptoms associated with CFC progression. However,
Figure 5. Identification of a zebrafish-CFC treatment window. (A) Six CI-1040 treatments (A–F) and a control treatment (G) for zebrafish embryos expressing
CFC variant BRAFQ257R reveal that all drug treatments restore normal development at 10.5 hpf (treatments A–F), whereas only treatments A and B restore
normal development both at 10.5 and 27.5 hpf. Other drug treatments (C–F) cause additional developmental defects at 27.5 hpf, most notably, reduced posterior
development. (B) Six additional drug treatments (A–F) and a control treatment (G) for zebrafish-CFC variant BRAFQ257R show that the 4.5–5.5 hpf develop-
mental window is necessary for the prevention of zebrafish-CFC early phenotypes. The percentage of embryos displaying the phenotype is given at the lower
right of each image (a minimal of n ¼ 30/experiment). Blue bars represent embryo medium, whereas red bars represent CI-1040 treatment.
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because CFC mutations affect gastrulation (Fig. 1–3), and
have an early developmental treatment window (Fig. 5),
application of MEK inhibitors for CFC syndrome patients
may be severely limited. Nonetheless, because CFC syn-
drome has a progressive phenotype, and many of the pheno-
typic effects develop post-natally, patients may still be
helped by systemic therapies after birth (1).
We also provide evidence that the developmental effects of
the disease alleles can be prevented by the inhibition
of endogenous FGFR-signalling, with the exception of one
of the highest kinase-activating melanoma mutations,
BRAFV600E (Fig. 6). We reason that as normal gastrulation
involves endogenous FGFR signalling, FGFR inhibition
reduces the total level of defective CFC BRAF or MEK signal-
ling, thereby preventing the altered cell movement phenotype.
This supports the idea that total MAPK signalling is important
in CFC development (Fig. 4), and also emphasizes the impor-
tance of testing the action of developmental syndrome mutant
alleles and inhibitors in a developing animal. In vitro, the CFC
BRAFQ257R and melanoma BRAFV600E mutant alleles both
promote similar high-kinase activity (7), and yet no individual
with CFC syndrome has been identified with a BRAFV600E
mutation. This demonstrates, for the first time, that the
BRAFV600E mutation is probably stronger in vivo than the
CFC mutations.
The high conservation of the MAPK signalling pathway
means that our CFC chemical-genetic studies in zebrafish
embryos will be relevant to the development of future pre-
clinical models of CFC. For example, mice exhibiting Apert-
like syndrome from dominant mutations in fibroblast growth
factor receptor-2 can be treated pre- and post-natally with
the small molecule MEK inhibitor, U0126 (41). We note,
however, that similar comprehensive CFC allele comparisons,
coupled with multiple treatment testing, within the short-time
span described here, is not currently feasible in mouse models.
This makes the zebrafish system a tractable tool for medical
and research geneticists to explore allele activity and thera-
peutic potential. This work establishes a foundation to
propel forward the clinical discussion and scientific strategy
for assessing the suitability of using currently available
cancer drugs to treat the progressive phenotypes of CFC in
children.
Figure 6. Treatment of BRAF, MEK1 and MEK2 variants with SU-5402. (A) The mutant phenotypes promoted by the RNA expression of BRAF variants are
prevented by pharmacological treatment with the FGFR1 inhibitor SU-5402, with the exception of the developmental phenotype caused by BRAFV600E.
(B) Similarly, the elongation promoted by MEK1 and MEK2 disease variants is prevented by SU-5402 treatment. (C) Western blotting of total zebrafish
lysates for ERK and phospho-ERK protein shows that SU-5402 treatment causes reduction of ERK phosphorylation, with a-tubulin as a loading control.
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MATERIALS AND METHODS
Animal husbandry
Adults and zebrafish embryos were raised and maintained at
28.58C. Embryos were acquired by pair matings of AB and
TL zebrafish lines.
Cloning and RNA production
Patient and engineered BRAF, MEK1 and MEK2 DNA were
cloned into pENTR 3C (Invitrogen), and using the Gatewayw
(Invitrogen) technology the DNA sequences were subcloned
into the pDEST17 (Invitrogen) vector. Expression vectors
were linearized, and in vitro transcription of synthetic
capped mRNA was performed using the T7 RNA polymerase
mMESSAGE mMACHINE Kit (Ambion).
Microinjection of embryos
Injections were performed on WT zebrafish embryos using a
nitrogen-powered Picospritzer III microinjector (Intracel) con-
jugated to a Nikon SMZ 1000 stereomicroscope. One-cell
stage embryos were injected with 35 pg (optimal) or 15 pg
(suboptimal) of capped mRNA and were monitored until
throughout the first 24 h of development.
Pharmacological inhibition of FGF and MAPK signalling
To test the prevention of the mRNA-promoted phenotype,
4 hpf embryos injected with mRNA were treated with small
molecule inhibitors. To inhibit FGFR1 activity, embryos
were incubated in SU5402 (Calbiochem) at 1 mM in E3
embryo medium (42) at 28.58C in the dark. To inhibit
MEK1/2, embryos were treated with 1 mM CI-1040 and 1or
7 mM PD-0325901 (University of Dundee) in E3 embryo
medium at 28.58C as previously described (30).
Whole-mount RNA in situhybridization
Embryos collected at the tail-bud stage were fixed overnight in
4% parafolmaldehyde/PBS at 48C, were hand-dechorionated
and dehydrated overnight in methanol at 2208C. In vitro tran-
scribed digoxigenin-labelled antisense RNA probes were syn-
thesised (Roche). Dlx3 and HggI riboprobes (15) and
whole-mount in situ hybridization were carried out following
previously described protocols (43). Anti-digoxigenin anti-
serum alkaline phosphatase was incubated in a 1:5000 dilution
overnight and the samples were washed in BCL3 solution (1 M
Tris pH 9.5, 5 M NaCl, 0.5 M MgCl2, 20% Tween 20). The
embryos were, subsequently, stained in 500 ml of BM Purple
alkaline phosphatase (Roche) for 30–45 min and the reaction
was stopped in 20 mM EDTA/PBS. Processed embryos were
imaged using a Nikon SMZ1500 stereomicroscope in conjunc-
tion with a Nikon Coolpix 5400 camera.
Protein blotting
Embryo buffer was removed, and tail-bud stage embryos were
frozen at 2808C. Samples were ribolyzed for 5 s in protein
extraction buffer [2 M Tris pH 7.5, 5 M NaCl, 1% NP40, Na
deoxycholate, 10% SDS, 0.5 M NaF, 1 M b-glycosyl phos-
phate, protease inhibitor cocktail tablet (Roche)]. The
protein content was measured and the samples were normal-
ized. Total protein extracts were analyzed by western blotting,
probed with antibodies raised in rabbit [p44/42 MAPK
(1:2000) (Cell Signaling)] and in mouse [phospho p44/42
Figure 7. Evaluation of CFC-disease variant in vivo activity and potential treatment. Schematic representation of the zebrafish-based approach designed to
examine the in vivo significance of BRAF and MEK CFC disease mutations. (A) Microinjection of BRAF or MEK CFC variant mRNA into the single-cell
zebrafish embryo promoted an elongated zebrafish embryo at 10 hpf that gives rise to an animal with severe development defects, including axis formation,
and heart defects at 24 hpf (red arrow). (B) Treatment of CFC-microinjected embryos with inhibitors of the FGF-MAPK signalling pathway (green) restores
normal development to the CFC-zebrafish embryo, possibly by restoring appropriate total levels of MAPK-signalling (green arrows).
2552 Human Molecular Genetics, 2009, Vol. 18, No. 14
MAPK (E10) (1:2000), c-myc (9E10) (1:2000) (Sigma),
a-tubulin B-5-1-2 (1:50000) (Santa Cruz)]. Secondary anti-
bodies conjugated to horseradish peroxidase were used to
detect the proteins.
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